Two causes of demyelinating neuropathy in one patient: CMT1A and POEMS syndrome.
Chahin
Nizar
N
Zeldenrust
Steven R
SR
Amrami
Kimberly K
KK
Engelstad
Janean K
JK
Dyck
P James B
PJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001804:Blood Transfusion, Autologous; D001842:Bone and Bones / Q000473:pathology / Q000503:physiopathology; D005871:Castleman Disease / Q000150:complications* / Q000235:genetics / Q000503:physiopathology; D002607:Charcot-Marie-Tooth Disease / Q000150:complications* / Q000235:genetics* / Q000503:physiopathology; D004252:DNA Mutational Analysis; D003711:Demyelinating Diseases / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D003937:Diagnosis, Differential; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D040582:Inheritance Patterns / Q000235:genetics; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D016878:POEMS Syndrome / Q000150:complications* / Q000235:genetics* / Q000503:physiopathology; D010375:Pedigree; D010525:Peripheral Nerves / Q000473:pathology / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000097:blood